PMLiVE5d
Eli Lilly’s mirikizumab shows promise in phase 3 Crohn’s disease study
Eli Lilly has shared one-year histologic outcomes from a phase 3 study of its interleukin-23p19 antagonist mirikizumab in ...
PMLiVE5d
FDA advisory committee recommends Stealth’s elamipretide for Barth syndrome
A US Food and Drug Administration (FDA) panel of experts has voted in support of Stealth BioTherapeutics’ elamipretide for ...
PMLiVE12d
J&J’s Erleada shows overall survival benefit in head-to-head prostate cancer study
Johnson & Johnson (J&J) has announced results from a real-world study comparing its Erleada (apalutamide) to Pfizer and ...
PMLiVE10d
Astellas and AviadoBio enter exclusive dementia gene therapy deal worth over $2bn
Astellas Pharma and AviadoBio have entered into an exclusive option and licence agreement worth over $2bn for an ...
PMLiVE12d
Navigating US payer evidence needs to optimise market access
What clinical and economic evidence do US payers prefer to drive formulary decisions? How can you optimise your chances of ...
PMLiVE11d
Merck’s Keytruda shows promise as perioperative head and neck cancer treatment
Merck & Co – known as MSD outside the US and Canada – has shared positive results from a late-stage study of its anti-PD-1 therapy in head and neck cancer. The phase 3 KEYNOTE-689 trial has been ...
PMLiVE13d
AstraZeneca gains rights to CSPC’s lipid-lowering therapy in deal worth over $1.9bn
AstraZeneca (AZ) has entered into an exclusive licence agreement worth over $1.9bn to advance CSPC Pharmaceutical Group’s pre-clinical lipid-lowering therapy, strengthening the Anglo-Swedish drugmaker ...
PMLiVE13d
AbbVie shares promising late-stage results for Parkinson’s disease candidate tavapadon
AbbVie has shared positive top-line results from a late-stage study of its investigational Parkinson’s disease (PD) drug in adults. The phase 3 TEMPO-1 trial evaluated two fixed doses of the D1/D5 ...
PMLiVE9d
Eli Lilly and insitro collaborate to advance new treatments for metabolic diseases
Eli Lilly has partnered with insitro to advance new treatments for metabolic diseases, including metabolic dysfunction-associated steatotic liver disease (MASLD). The new drugs developed under the ...
PMLiVE11d
Behavioural Data Offering from Medscape Global
See more about this new insights product, Medscape AffinityTM, which offers unparalleled insights into the online behaviour of 13M+ HCPs to help you make fully informed decisions around your brand and ...
PMLiVE12d
ICR researchers reveal benefits of personalised radiotherapy for bladder cancer patients
Researchers from the Institute of Cancer Research (ICR) have highlighted the potential benefits of treating bladder cancer with personalised radiotherapy. More than 130,000 patients are treated on the ...
PMLiVE16d
Researchers develop new approach to target cells affected by motor neurone disease
It is hoped that preventing healthy cells from reading the molecules’ messages could lead to safer and more effective gene therapies for MND, as well as other neurodegenerative diseases, including ...